





Screening programmes have been devel-
oped for the surveillance of patients at risk
of hepatocellular carcinoma (HCC; mainly
liver cirrhosis) for the detection at an early
stage, ie, suspicious liver nodules not
larger than 2 cm in diameter often
detected by ultrasound. Treatment indi-
cation needs a clear diagnosis for which
one option is a biopsy often hampered by
a relevant rate of false negatives and by
a risk of bleeding and malignant seeding.
Therefore, for the diagnosis of HCC
imaging criteria are preferred requiring
contrast enhancement and dynamic
imaging. The recent update of the Amer-
ican Association for the Study of Liver
Diseases (AASLD) guidelines in 20101
recommends for a nodule greater than
1 cm one single imaging technique to be
used among CT and MRI, and in the case
of non-diagnostic criteria the choice
between a second technique or a biopsy.
Establishing HCC diagnosis at an ideal
size of less than 2 cm relates to the tran-
sition from low to high grade dysplasia
and very early HCC as described by the
international working party classification2
and a final international diagnostic
consensus.3 From two types of HCC less
than 2 cm, early HCC has a vaguely
nodular appearance, is well differentiated
and corresponds to the very early HCC
stage of the Barcelona Clinic Liver Cancer
classification, with the absence of micro-
vascular invasion excluding a clear
imaging profile for diagnosis. The
progressed HCC has a distinctly nodular
pattern, is more moderately differentiated
and often with evidence of microvascular
invasion. As the diagnostic sensitivity of
biopsy may also be limited in very early
HCC because of its composition by well
differentiated hepatocytes, the additional
use of genomic biomarkers has been
introduced. According to a study for the
diagnosis of early HCC, a 3-gene set
obtained a discriminatory accuracy of 94%
with glypican-3 (GPC3) of most predictive
power.4 GPC35 is a cell-surface heparan
sulphate proteoglycan secreted into
plasma, its immunoreactivity is cyto-
plasmic, sometimes membranous or
canalicular, seldom only focal.3 Another
study6 identified heat-shock protein 70
(HSP70) as the most abundantly upregu-
lated gene in early HCC components.
HSP70 is implicated in the regulation of
cell cycle progression, in apoptosis and in
tumorigenesis. Its nucleocytoplasmic and
mostly focal immunoreactivity is found in
most HCC including early and well-
differentiated forms.3 Another profiling
HCC study7 identified one clone as the
glutamine synthetase (GS) transcript
expressed and tightly regulated during
development in the hepatic lobule. In
human HCC, an upregulation of GS
messenger RNA, protein and activity was
described as well as a stepwise increase in
GS immunoreactivity from precancerous
lesions to early HCC with strong and
diffuse staining intensity.5
Di Tommaso et al8 performed a retro-
spective immunohistochemistry marker
study of HSP70, GPC3 and GS aiming at
the distinction of high-grade dysplasia
from well-differentiated HCC in 18 to
19-gauge needle liver biopsy specimens
comprising large regenerative nodules (13),
low-grade (21) and high-grade dysplastic
nodules (50), very well-differentiated (17),
well-differentiated (40) and moderately
poorly differentiated (35) HCC. Using at
least two markers positive for the differ-
entiation of HCC from non-malignant
nodules, the sensitivity, specificity, posi-
tive predictive value and accuracy rates
were 58.7%, 100%, 100% and 78.4%,
respectively, and for differentiating high-
grade dysplastic nodules from very well-
differentiated HCC, were still 49.1%,
100%, 100% and 72.9%, respectively.
In their paper published in Gut, Cai
et al9 (see page 967) try to improve the
immunohistological diagnosis of HCC in
liver biopsies by implementing in addition
to the biomarkers HSP70 and GPC3 the
molecular marker enhancer of zeste
homolog 2 (EZH2) known for its impor-
tant role in hepatocellular carcinoma
tumorigenesis. EZH2 is the histone H3
lysine 27 methyltransferase of polycomb-
repressive complex 2 (PRC2), mediates
transcription silencing, and has been
shown to maintain cell identity, cell cycle
regulation and oncogenesis.10
The authors investigated retrospectively
by immunohistochemistry the expression
dynamics of EZH2, HSP70 and GPC3 in
two independent surgical testing (212
HCC) and validation (126 HCC, 37
dysplastic nodules) cohorts of HCC
patients in order to evaluate their diag-
nostic yield for HCC detection. The
criteria obtained there were then applied
to the diagnostic performance of 18-gauge
needle biopsies from 72 HCC and 57
different precancerous lesions from
nodules less than 3 cm in diameter of an
additional biopsy cohort with consecu-
tively confirmed diagnosis from surgical
specimens following operation. By
immunohistochemistry analysis the
sensitivity and specificity of EZH2 for
HCC detection was 95.8% and 97.8% in
the testing corhort, with lower results
in the validation cohort (83.3%, 90.0%).
For the diagnosis of well-differentiated
HCC, these rates amounted to 68.9% and
91.5% (EZH2), 62.5% and 98.5% (HSP70),
50.0% and 92.1% (GPC3), and to 75.0%
and 100.0% for the three marker panel,
respectively.
In fine-needle biopsies, positive cases for
at least one panel marker consecutively
increased from large regenerative nodules
(0/6) and hepatocellular adenomas (0/6)
to focal nodular hyperplasias (2/20, 10%),
dysplastic nodules (7/25, 28%), well-
differentiated HCC (16/18, 88.9%) and
moderately/poorly differentiated HCC
(54/54, 100%). Considering at least two
positive panel markers, positive cases were
detected in none of the large regenerative
nodules/hepatocellular adenomas, focal
nodular hyperplasias and dysplastic
nodules, but in 11/18 (61.1%) well-differ-
entiated HCC, 32/37 (86.5%) moderately
differentiated HCC and 15/17 (88.2%)
poorly differentiated HCC. Accordingly,
the relevant statistical parameters of
sensitivity, specificity, positive predictive
value and negative predictive value at
a prevalence of 55.8%, accuracy and
Youden index (J) values changed from
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97.2%, 84.2%, 88.6%, 96.0%, 91.5% and
0.81, respectively, for at least one marker
positive to 80.6%, 100%, 100%, 80.3%,
89.2% and 0.81, respectively, for at least
two positive markers. These findings
qualify EZH2 protein as a promising
diagnostic biomarker of HCC and the use
of the three marker panel as a significant
improvement of HCC detection in liver
biopsy tissues.
Despite the intriguing study findings
some limitations have to be considered:
first, the study is of retrospective nature
and is thus less reliable than a prospective
study. Second, only patients with lesions
confidently classified as HCC by biopsy
and explant analysis were included in the
study, while excluding cases without later
operation.
Third, the evaluation criteria of biopsy
specimens were derived from the surgically
resected specimens of the testing and vali-
dation cohorts including a high propor-
tion of large HCC lesions (60% >5 cm in
diameter, 56% stages III and IV cases),
which only afford a haematoxilineeosin
staining for confident histological HCC
diagnosis. However, the authors have
not specified the size of their surgically
resected tumours (or non-tumours) for
confirmation of biopsy diagnosis.
It is understood that well-established
criteria for an unequivocal HCC diagnosis
are also needed for the inclusion of
genomic biomarkers and their final vali-
dation. Therefore, further prospective
studies with a predominant inclusion of
HCC lesions of less than 2 cm in diameter
are needed for the final validation and
confirmation of the conclusions of this
interesting study.
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Prebiotic carbohydrates: not
sweet yet for Crohn’s disease?
Philippe Marteau1,2,3
The double-blind placebo controlled study
performed by Benjamin et al1 published in
Gut (see page 923) shows that the daily
consumption of 15 g fructo-oligosaccha-
rides (FOS) worsens the clinical signs of
active Crohn’s disease. The message for
the clinician and the patient is clear:
despite a strong rationale and hopes from
open studies,2 there is presently no
evidence of efficacy of prebiotics in
Crohn’s disease. The same conclusion
applies for probiotics and synbiotics.3
However, one should avoid throwing the
baby out with the bath water.
Descriptive studies of themicrobiota and
microenvironment in Crohn’s disease have
repeatedly shown dysbiosis, which is prob-
ably partly a consequence of the ecological
modifications induced by the disease but
also a worsening factor.4 It is thus impor-
tant to obtain knowledge on both the
positive and detrimental consequences of
manipulating the microbiota in the various
clinical situations of the disease.3
FOS are non-digestible oligosaccharides,
and as such exhibit an osmotic effect and
increase fermentation (gas and short chain
fatty acids and low pH at least in the right
colon).5 6 Moreover, they usually have
prebiotic properties, especially a bifido-
genic effect (ie, they increase concentra-
tions of bifidobacteria in the colonic
lumen).6 These metabolic characteristics
(osmotic effect and fermentation) explain
their potential risks of increasing gas
production, bloating, abdominal pain and
diarrhoea.5 The osmotic effect depends on
the chain length and the results obtained
here with synergy1 may not apply to other
FOSwith a longer chain length. The bet for
any trial is the hope that, at the chosen
dose, efficacy would overweight those
predictable dose-dependent side effects.
Clinicians must keep on advising
patients with inflammatory bowel disease
complaining of bloating or diarrhoea
to restrict their consumption of non-
digestible oligosaccharides (lactose in milk,
sugar alcohols and FOS).7 They should
explain diet and correct any confusing
information (often coming from the
internet) including advertisements for
products without any clinical study. The
probiotic Lactobacillus rhamnosus GG is an
example in which optimistic open studies
were followed by well-designed negative
randomised controlled trials in patients.8 9
The study by Benjamin et al1 also brings
important new facts to the researcher and
raises new questions. Indeed, FOS did not
exhibit a bifidogenic effect and this
contrasts with trials in healthy subjects in
whom FOS at this dose is usually well
tolerated and has a bifidogenic effect.6Why
was that? Is it just because the endogenous
levels of bifidobacteria were already quite
high in the patients?1 6 A short colonic
transit time may also play a role.
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